Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01738815 · ClinicalTrials.gov registry record · Early Phase 1
Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer
A Early Phase 1 study, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 43
- Enrollment target
NCT01738815: Completed Early Phase 1 study, sponsored by State University of New York - Upstate Medical University.
NCT01738815 is a Early Phase 1 study that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 43 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (19% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01738815, a Early Phase 1 study, has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The goal of this study is to test whether the drug valproic acid can cause changes in bladder tumors that might inhibit their growth.
Primary Outcome
Expression of thrombospondin-1 will be assayed using quantitative real-time PCR and western blotting. Comparisons will be intra-patient for paired specimens acquired prior to and after treatment and inter-patient for treated and un-treated patients.
Interventions
- DRUG Valproic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-04 |
| Phase | Early Phase 1 |
What the finished NCT01738815 record still lists
NCT01738815 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (19% lower).
The record links to 0 conditions, and to 1 intervention - of which Valproic Acid is the first listed.
NCT01738815 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01738815 about?
NCT01738815 is a clinical study titled "Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer". The goal of this study is to test whether the drug valproic acid can cause changes in bladder tumors that might inhibit their growth.
What is the current status of trial NCT01738815?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 43 participants. The study started on 2011-12. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01738815?
The interventions under investigation include: Valproic Acid (DRUG).
Who is sponsoring clinical trial NCT01738815?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01738815's enrollment target sits among peer trials
43 600th of 2000 higher than 1,397 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia